V. Blatt

1.9k total citations · 1 hit paper
17 papers, 1.5k citations indexed

About

V. Blatt is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, V. Blatt has authored 17 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 10 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in V. Blatt's work include Glioma Diagnosis and Treatment (16 papers), Brain Metastases and Treatment (9 papers) and Histone Deacetylase Inhibitors Research (7 papers). V. Blatt is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Brain Metastases and Treatment (9 papers) and Histone Deacetylase Inhibitors Research (7 papers). V. Blatt collaborates with scholars based in Italy. V. Blatt's co-authors include Alba A. Brandes, Enrico Franceschi, Mario Ermani, Alicia Tosoni, Roberta Bertorelle, Giovanni Tallini, Annalisa Pession, A. Tosoni, Stefania Bartolini and Marco Leonardi and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

V. Blatt

17 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

2008 634 citations Alba A. Brandes, Enrico Franceschi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Blatt Italy	10	1.3k	607	372	364	291	17	1.5k
Hans J.J.A. Bernsen Netherlands	12	1.4k 1.1×	690 1.1×	478 1.3×	386 1.1×	550 1.9×	19	1.8k
Leighann Bailey United States	7	1.3k 1.0×	509 0.8×	468 1.3×	220 0.6×	457 1.6×	13	1.5k
Nancy Garren United States	4	1.0k 0.8×	396 0.7×	361 1.0×	175 0.5×	331 1.1×	4	1.3k
Paul Duic United States	3	1.0k 0.8×	393 0.6×	380 1.0×	172 0.5×	335 1.2×	5	1.3k
Janet Bruner United States	12	1.1k 0.8×	648 1.1×	420 1.1×	117 0.3×	233 0.8×	22	1.5k
Lynn S. Ashby United States	20	1.1k 0.8×	361 0.6×	304 0.8×	200 0.5×	196 0.7×	46	1.6k
Soufiane El Hallani Canada	13	810 0.6×	341 0.6×	546 1.5×	206 0.6×	520 1.8×	23	1.5k
S. Asbell United States	3	878 0.7×	505 0.8×	142 0.4×	297 0.8×	151 0.5×	8	1.1k
Brian Haylock United Kingdom	17	654 0.5×	279 0.5×	259 0.7×	201 0.6×	236 0.8×	42	1.2k
Walter Curran United States	5	738 0.6×	404 0.7×	158 0.4×	213 0.6×	195 0.7×	8	940

Countries citing papers authored by V. Blatt

Since Specialization

Citations

This map shows the geographic impact of V. Blatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Blatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Blatt more than expected).

Fields of papers citing papers by V. Blatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Blatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Blatt. The network helps show where V. Blatt may publish in the future.

Co-authorship network of co-authors of V. Blatt

This figure shows the co-authorship network connecting the top 25 collaborators of V. Blatt. A scholar is included among the top collaborators of V. Blatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Blatt. V. Blatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Brandes, Alba A., A. Tosoni, Enrico Franceschi, et al.. (2009). Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology. 64(4). 769–75. 73 indexed citations

2.

Tosoni, A., Enrico Franceschi, Mario Ermani, et al.. (2008). Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. Journal of Neuro-Oncology. 89(2). 179–185. 62 indexed citations

3.

Brandes, Alba A., Enrico Franceschi, Alicia Tosoni, et al.. (2008). MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. Journal of Clinical Oncology. 26(13). 2192–2197. 634 indexed citations breakdown →

4.

Brandes, Alba A., Enrico Franceschi, Alicia Tosoni, V. Blatt, & Mario Ermani. (2007). Long‐term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 110(9). 2035–2041. 100 indexed citations

5.

Franceschi, Enrico, Giovanni Cavallo, Sara Lonardi, et al.. (2007). Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer. 96(7). 1047–1051. 163 indexed citations

6.

Franceschi, Enrico, A. Tosoni, V. Blatt, et al.. (2007). 2518 POSTER Prolonged maintenance chemotherapy with Temozolomide (TMZ) after concomitant treatment in newly diagnosed GBM: safety profile. European Journal of Cancer Supplements. 5(4). 232–233. 1 indexed citations

7.

Franceschi, Enrico, A. Tosoni, Mario Ermani, et al.. (2007). Should adult medulloblastoma patients at low risk receive adjuvant chemotherapy? Long-term results of a prospective study. Journal of Clinical Oncology. 25(18_suppl). 2018–2018. 1 indexed citations

8.

Tosoni, A., Enrico Franceschi, V. Blatt, et al.. (2007). 2507 POSTER Temozolomide (TMZ) concomitant to radiotherapy (RT) plus 12 cycles of maintenance chemotherapy in newly diagnosed GBM: is more better?. European Journal of Cancer Supplements. 5(4). 229–229. 1 indexed citations

9.

Brandes, Alba A., A. Tosoni, Giovanni Cavallo, et al.. (2006). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). British Journal of Cancer. 95(9). 1155–1160. 185 indexed citations

10.

Brandes, Alba A., et al.. (2006). Glioblastoma in the elderly: Current and future trends. Critical Reviews in Oncology/Hematology. 60(3). 256–266. 33 indexed citations

11.

Tosoni, A., Giovanni Cavallo, Mario Ermani, et al.. (2006). Is protracted low-dose temozolomide feasible in glioma patients?. Neurology. 66(3). 427–429. 33 indexed citations

12.

Tosoni, Alicia, et al.. (2006). Prognostic factors for anaplastic astrocytomas. Journal of Neuro-Oncology. 81(3). 295–303. 25 indexed citations

13.

Brandes, Alba A., Alicia Tosoni, Giovanna Cavallo, et al.. (2006). Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. Journal of Clinical Oncology. 24(29). 4746–4753. 142 indexed citations

14.

Brandes, Alba A., A. Tosoni, Giovanni Cavallo, et al.. (2006). Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: A phase II GICNO study. Journal of Clinical Oncology. 24(18_suppl). 1514–1514. 4 indexed citations

15.

Brandes, Alba A., Giovanni Cavallo, A. Tosoni, et al.. (2005). Temozolomide (TMZ) for progressive primitive brain tumors: safety at 75 mg/m² a day for 21 days every 28: A GICNO (Italian Neuro-Oncology Group) study. Journal of Clinical Oncology. 23(16_suppl). 1541–1541. 1 indexed citations

16.

Brandes, Alba A., A. Tosoni, Michele Reni, et al.. (2004). Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group). Journal of Clinical Oncology. 22(14_suppl). 1516–1516. 1 indexed citations

17.

Brandes, Alba A., A. Tosoni, Michele Reni, et al.. (2004). Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group). Journal of Clinical Oncology. 22(14_suppl). 1516–1516. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact